贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液的效果和安全性

doi:11.3969/j.issn.1674-8115.2015.08.020

摘要/Abstract

摘要：

目的探讨胸腔内给予贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液的效果及安全性。方法 54例非小细胞肺癌伴恶性胸腔积液患者根据不同的治疗方案分为单纯顺铂治疗组（对照组，n=26）和贝伐单抗联合顺铂治疗组（联合治疗组，n=28)。对照组方案：顺铂，75 mg/m²，胸腔注射，分成2次,每个周期为21 d。联合治疗组方案：贝伐单抗，5 mg/kg，胸腔注射2次，一个周期为21 d；顺铂的胸腔注射剂量和方法与对照组相同。两组患者均给予全身化学治疗（化疗）。每周期前测定胸腔积液量及胸腔积液中血管内皮生长因子（VEGF）含量，根据胸腔积液控制率和疾病控制率评价疗效。观察治疗过程中不良反应的发生情况。结果治疗结束后，联合治疗组和对照组胸腔积液控制率分别为85.7%和69.2%，疾病控制率分别为96.4%和80.8%，差异均有统计学意义（P<0.05）。在治疗的各个周期，联合治疗组胸腔积液控制率均显著高于对照组（P<0.05）。与治疗前比较，治疗后联合治疗组和对照组胸腔积液中VEGF含量均有所减少，联合治疗组更为明显（P<0.05）。与对照组比较，联合治疗组无新增及加重的不良反应发生。结论对于非小细胞肺癌患者的胸腔积液，贝伐单抗联合顺铂胸腔注射是一种有效且安全的治疗方法。

关键词: 胸腔积液, 非小细胞肺癌, 贝伐单抗, 顺铂

Abstract:

Objective To explore the therapeutic effect and safety of intrathoracic injection of bevacizumab combined with cisplatin on malignant pleural effusion (MPE) of patients with non-small cell lung cancer (NSCLC). Methods A total of 54 NSCLC patients with MPE were randomly divided into the cisplatin group (control group, n=26) and bevacizumab combined with cisplatin group (combined treatment group, n=28) according to different treatment plans. Patients of the control group received intrathoracic injection of cisplatin of 75 mg/m² twice and each cycle was 21 d. Patients of the combined treatment group received intrathoracic injection of bevacizumab of 5 mg/kg twice and each cycle was 21 d, and the administration of cisplatin was the same as the control group. Patients of two groups all underwent systemic chemotherapy. The volume of pleural effusion and the level of vascular endothelial growth factor (VEGF) in pleural effusion were measured before each cycle. The therapeutic effect was evaluated according to control rates of pleural effusion and disease. The incidence of adverse reactions during the treatment was observed. Results The control rates of pleural effusion of the combined treatment group and control group were 85.7% and 69.2% and the control rates of disease were 96.4% and 80.8% after treatment. The differences were statistically significant (P<0.05). The control rate of pleural effusion of the combined treatment group was significantly higher than that of the control group at each stage of treatment (P<0.05). The VEGF levels in pleural effusion of the combined treatment group and control group after treatment were lower than those before treatment and the reduction of pleural effusion of the combined treatment group was more remarkable (P<0.05). Compared with the control group, new or aggravating adverse reactions were not found in the combined treatment group. Conclusion Intrathoracic injection of bevacizumab and cisplatin is an efficient and safe treatment method for NSCLC patients with malignant pleural effusion.

Key words: malignant pleural effusion, non-small cell lung cancer, bevacizumab, cisplatin

陈雷，夏书月. 贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液的效果和安全性[J]. 上海交通大学学报（医学版）, doi: 11.3969/j.issn.1674-8115.2015.08.020.

CHEN Lei, XIA Shu-yue. Therapeutic effect and safety of bevacizumab combined with cisplatin on malignant pleural effusion of patients with non-small cell lung cancer[J]. , doi: 11.3969/j.issn.1674-8115.2015.08.020.

[1]	马韵芳, 潘丽娜, 李圳, 高蓓莉, 胡家安, 徐志红. 司美替尼下调KRAS G12V突变型非小细胞肺癌细胞PD-L1水平的探索性研究[J]. 上海交通大学学报(医学版), 2021, 41(6): 741-748.
[2]	童桐, 秦星, 谢非, 蒋英英, 石剑波, 张建军. USP47通过促进抗凋亡蛋白表达介导头颈鳞癌细胞顺铂耐药[J]. 上海交通大学学报(医学版), 2021, 41(4): 434-441.
[3]	伍科1，姚智显 1，郑重1*，程蕾蕾 2，刘志宏 1. 顺铂通过杀伤粒样髓系抑制细胞促进膀胱癌小鼠心力衰竭[J]. 上海交通大学学报（医学版）, 2019, 39(9): 1011-.
[4]	周培慧，王丽. 白细胞介素 -27在顺铂所致急性肾损伤中的高表达及对细胞凋亡的抑制作用[J]. 上海交通大学学报（医学版）, 2019, 39(4): 372-.
[5]	袁园，糜军. 谷丙转氨酶2对胃癌顺铂治疗抵抗的影响及其作用机制[J]. 上海交通大学学报（医学版）, 2019, 39(10): 1134-.
[6]	屈国君 1，陆元凤 2，李宇 1. PDGFRα下游新底物 CCT2对肿瘤细胞生长的影响及其机制[J]. 上海交通大学学报（医学版）, 2019, 39(1): 28-.
[7]	曹淑慧，周严，李静文，钟华. DCVAC/LuCa联合化疗治疗晚期非小细胞肺癌安全性的探讨[J]. 上海交通大学学报（医学版）, 2018, 38(8): 923-.
[8]	何亚平 1，楼玮群 2，陈杰灵 2，周箴 3，朱静芬 1，简红 3. 病程12个月及以上非小细胞肺癌患者生活质量评估及影响因素研究[J]. 上海交通大学学报（医学版）, 2018, 38(7): 775-.
[9]	胡章国，曹淑慧，钟华 . EGFR-TKI 对少见EGFR 21L861Q 突变的晚期非小细胞肺癌患者的治疗效果[J]. 上海交通大学学报（医学版）, 2017, 37(11): 1524-.
[10]	石琴, 陈群, 谢强，等. EGFR野生型NSCLC患者ERCC1、RRM1、TYMS和TUBB3 mRNA表达水平对化疗效果和预后的影响[J]. 上海交通大学学报（医学版）, 2015, 35(7): 1010-.
[11]	徐海燕，许远帆，闫宁宁，等. 18F-FDG-PET/CT早期预测复发转移非小细胞肺癌的缓解率和生存期的临床研究[J]. 上海交通大学学报（医学版）, 2015, 35(11): 1641-.
[12]	黄鸿渤，谢廷洪，苏明航，等. 电视胸腔镜和传统开胸术对非小细胞肺癌患者围手术期外周循环肿瘤细胞水平的影响[J]. 上海交通大学学报（医学版）, 2014, 34(8): 1171-.
[13]	李勇，李子明，陆舜. 早期非小细胞肺癌表皮生长因子受体基因突变分布[J]. 上海交通大学学报（医学版）, 2014, 34(4): 511-.
[14]	王琳，娄加陶. microRNA-128a对非小细胞肺癌细胞增殖和迁移的影响[J]. 上海交通大学学报（医学版）, 2014, 34(3): 268-.
[15]	周荻, 徐欣, 谢华英, 等. 全脑放疗联合靶向治疗与同步放、化疗治疗非小细胞肺癌脑转移疗效分析[J]. , 2013, 33(4): 480-.

贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液的效果和安全性

Therapeutic effect and safety of bevacizumab combined with cisplatin on malignant pleural effusion of patients with non-small cell lung cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics